Search results

Page results

• Camden Adult Pathway Partnership commended at London Homelessness Awards

  A healthcare project aimed at homeless people and delivered by UCLH has been specially commended in this year’s London Homelessness Awards.

• Series No 5 - Molecular Radiotherapy for adults having radioactive iodine (131I) treatment

  This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.

• Their Royal Highnesses Princesses Beatrice and Eugenie and Sarah, Duchess of York open blood cancer ward

  Sarah, Duchess of York, and Their Royal Highnesses Princess Beatrice and Princess Eugenie met with staff and young people in a video call to formally open the specialist haematology ward for young adults in the University College Hospital Grafton Way Building last week (Monday 11 July).

• Bidborough House mass vaccination centre closes

  Our mass vaccination centre at Bidborough House, which we have operated in partnership with UCL, closes on Friday 22 July.

• Robotic surgery for bladder cancer improves patient recovery time

  Robot-assisted surgery used to perform bladder cancer removal and reconstruction enables patients to recover far more quickly and spend significantly less time in hospital, concludes a trial led by UCLH, UCL and the University of Sheffield.

• Guy Noble - arts curator

  Art and creativity can be a real tonic for health, says UCLH arts curator Guy Noble.

• Understanding brain stem death - a guide for relatives

  This information explains brain stem death and the tests used to confirm the diagnosis. It aims to answer frequently asked questions.

• Contrast Extravasation (contrast leakage)

  Contrast Extravasation (contrast leakage) patient information leaflet

• Training programmes perform well in this year’s GMC National Training Survey

  We are pleased to have performed very well again in this year's General Medical Council National Training Survey.

• UCLH recruits first patient globally for new Alzheimer’s Disease trial

  UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.